Suppression of mitochondrial respiratory complex I by OXPHOS inhibitor may offer effective salvage therapies, which currently do not exist for RTS patients as well as for recurrent sporadic osteosarcoma patients with somatic RECQL4 mutations. Here, RECQL4 is linked to osteosarcoma.